Therefore, BH4 availability is a critical determinant of eNOS regulation in several pathologies (e.g., atherosclerosis) and it is a rational therapeutic target to restore NO-mediated endothelial function and reduce disease progression [39]. Here, NOS3 is linked to atherosclerosis.